EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advancements in breast cancer mRNA vaccines: Current development and future prospects

Wen Zheng, Wenjie Chen, Gyorgy Hutvagner, Laura Rangel-Sanchez, Wei Deng

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026

DOI: 10.1016/j.bbcan.2025.189515 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026. Verfasst von Wen Zheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Engineering, University of Technology Sydney, Sydney, NSW 2007, Australia. Hauptthemen laut MEDLINE: Breast Neoplasms, Cancer Vaccines, mRNA Vaccines, RNA, Messenger. Die Arbeit nennt 238 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Messenger RNA (mRNA) vaccines have become a transformative approach in immunotherapy and have attracted significant attention owing to their unprecedented success in controlling COVID-19. With their ability to flexibly and specifically encode tumour-associated antigens, along with their favorable safety profiles and scalable manufacturing, mRNA vaccines represent a highly promising platform for cancer treatment. Breast cancer is a heterogeneous disease and many of its subtypes are immunologically cold tumours, which has limited the progress of immunotherapy in this field. Recent studies have highlighted the potential of mRNA vaccines to reshape the tumour immune microenvironment in breast cancer. These vaccines can enhance antigen presentation, activate T cell responses, and convert immunologically cold tumours into immune-active ones. This review provides a comprehensive overview of recent advances in mRNA vaccine development for breast cancer with a focus on antigen selection, mRNA design, and delivery strategies. It also examines findings from both preclinical and clinical studies as well as recent progress in industrial development. Finally, we discuss the current challenges hindering the clinical translation and ethical considerations of mRNA vaccine technology and propose future directions to advance mRNA vaccine-based therapies for breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCancer VaccinesmRNA VaccinesRNA, MessengerVaccine DevelopmentVaccines, SyntheticHumansFemaleTumor MicroenvironmentAntigens, NeoplasmCOVID-19ImmunotherapyAnimalsSARS-CoV-2

Stichwörter der Autor:innen

antigen targetbreast cancerimmunotherapymRNA delivery systemsmRNA vaccine

Substanzen

Cancer VaccinesmRNA VaccinesRNA, MessengerVaccines, SyntheticAntigens, Neoplasm

Autor:innen und Institutionen

  • School of Biomedical Engineering, University of Technology Sydney, Sydney, NSW 2007, Australia.
  • Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical Uni…
  • School of Biomedical Engineering, University of Technology Sydney, Sydney, NSW 2007, Australia. Electronic address: wei.deng@uts.edu.au.

Zitieren

APA

Zheng, W., Chen, W., Hutvagner, G., Rangel-Sanchez, L., & Deng, W. (2026). Advancements in breast cancer mRNA vaccines: Current development and future prospects. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2025.189515

Vancouver

Zheng W, Chen W, Hutvagner G, Rangel-Sanchez L, Deng W. Advancements in breast cancer mRNA vaccines: Current development and future prospects. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026. doi:10.1016/j.bbcan.2025.189515

BibTeX
@article{Zheng2026,
  author = {Zheng, Wen and Chen, Wenjie and Hutvagner, Gyorgy and Rangel-Sanchez, Laura and Deng, Wei},
  title = {Advancements in breast cancer mRNA vaccines: Current development and future prospects},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2026},
  doi = {10.1016/j.bbcan.2025.189515}
}
Kostenlos starten →